Targeting RBM5 may help disrupt 'undruggable' MYC in childhood leukemia

Scientists from St. Jude Children's Research Hospital and collaborators person identified the RNA-binding macromolecule RBM5 arsenic a imaginable vulnerability successful a acceptable of difficult-to-treat puerility leukemias. They characterized however RBM5 regulates and interacts with the well-known cancer-driving macromolecule MYC, which has agelong been considered intolerable to efficaciously and straight people with existing crab drugs. The findings, published contiguous successful Leukemia, contiguous a caller accidental to make targeted therapeutic interventions.